Bio-Techne FY26 net earnings more than doubled to $240.68 million; net sales slip 0.38% to $1.22 billionPUBT·20 hours agoTECH-0.07%MKKGY+0.60%
Merck KGaA ADR Earnings Call Signals Confident OutlookTip Ranks·1 day ago, 07:29 PMTECH-0.07%MKKGY+0.60%
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its ShareholdersMorningStar·Aug 22 at 03:52 AMTECH-0.07%MKKGY+0.60%
Werewolf Therapeutics sells preclinical INDUCER, INDUKINE platforms to EMD Serono for USD 33 millionPUBT·Aug 20 at 03:07 PMHOWL-3.66%MKKGY+0.60%
BlackRock lifts Merck stake to 8.22% as shares rise, instruments fallPUBT·Aug 20 at 02:22 AMMKKGY+0.60%MRK
Remepy secures $36m funding for hybrid drug pipeline expansionPharmaceutical Technology·Aug 13 at 04:06 AMMKKGY+0.60%
Global New Material Warns of Interim Loss Despite Revenue Surge After Merck DealTip Ranks·Aug 10 at 10:09 AMMKKGY+0.60%06616+1.27%
Germany's Merck KGaA Raises Outlook on Robust Results, Easing Currency HeadwindsMorningStar·Aug 6 at 12:31 AMMKKGY+0.60%MRK
MRK: Upgraded 2026 guidance follows robust Q2 growth in Life Science and ElectronicsQuartr·Aug 6 at 12:12 AMMKKGY+0.60%TECH-0.07%
Merck KGaA Q2 EBITDA pre rises 9.4% to € 1.6 billion; net sales increase 3.4% to € 5.43 billionPUBT·Aug 6 at 12:10 AMMKKGY+0.60%MRK
From Bench to Breakthrough: Empowering the Next Generation of Science CommunicatorsMorningStar·Aug 4 at 04:49 AMMKKGY+0.60%MRK
